HUP0102839A2 - Lanreotide-szomatosztatin analóg alkalmazása gyógyszerkészítmények előállítására és az azt tartalmazó gyógyszerkészítmények - Google Patents

Lanreotide-szomatosztatin analóg alkalmazása gyógyszerkészítmények előállítására és az azt tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0102839A2
HUP0102839A2 HU0102839A HUP0102839A HUP0102839A2 HU P0102839 A2 HUP0102839 A2 HU P0102839A2 HU 0102839 A HU0102839 A HU 0102839A HU P0102839 A HUP0102839 A HU P0102839A HU P0102839 A2 HUP0102839 A2 HU P0102839A2
Authority
HU
Hungary
Prior art keywords
hypertension
syndrome
cys
pancreatic
lanreotide
Prior art date
Application number
HU0102839A
Other languages
English (en)
Inventor
Jacques-Pierre Moreau
Original Assignee
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. filed Critical Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S.
Publication of HUP0102839A2 publication Critical patent/HUP0102839A2/hu
Publication of HUP0102839A3 publication Critical patent/HUP0102839A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgya H-b-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys- Thr-NH2 - aképletben a két cisztein diszulfidkötéssel kapcsolódik - vagy valamelygyógyszerészetileg elfogadható sója alkalmazása az alábbi betegségekvagy állapotok kezelésére alkalmas gyógyszerkészítményekelőállítására: szisztémás sclerosis, hasnyálmirigy pszeudociszták,hasnyálmirigy hasvízkór, VIPoma, nesidoblastosis, hyperinsulinémia,gastrinoma, Zollinger-Ellison szindróma, hyperszekréciós hasmenés,scleroderma, irritálható bél szindróma, felső gastrointestinálisvérzés, postprandialis venae portae hypertensio, portalishypertensioval összefüggő komplikációk, vékonybél elzáródás, duodeno-gyomor reflux, Cushing-féle szindróma, gonadotropinoma,hyperparathyroidismus, diabeteszes neuropathya, maculás degeneráció,rosszindulatú hypercalcemia, Paget-féle betegség, meningioma, rákoscachexia, psoriasis, hypertensio és pánik rohamok. A találmány tárgyamég a fenti vegyületet tartalmazó gyógyszerkészítmény. Ó
HU0102839A 1998-07-30 1999-07-29 Methods of using lanreotide, a somatostatin analogue and pharmaceutical compositions comprising thereof HUP0102839A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12652598A 1998-07-30 1998-07-30
US9469398P 1998-07-30 1998-07-30
PCT/US1999/017294 WO2000006185A2 (en) 1998-07-30 1999-07-29 Methods of using lanreotide, a somatostatin analogue

Publications (2)

Publication Number Publication Date
HUP0102839A2 true HUP0102839A2 (hu) 2002-01-28
HUP0102839A3 HUP0102839A3 (en) 2002-02-28

Family

ID=26789150

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102839A HUP0102839A3 (en) 1998-07-30 1999-07-29 Methods of using lanreotide, a somatostatin analogue and pharmaceutical compositions comprising thereof

Country Status (16)

Country Link
EP (1) EP1100532A2 (hu)
JP (1) JP2002521456A (hu)
KR (1) KR20010071071A (hu)
CN (1) CN1334742A (hu)
AR (1) AR023633A1 (hu)
AU (2) AU770193B2 (hu)
BR (1) BR9912609A (hu)
CA (1) CA2335654A1 (hu)
CZ (1) CZ2001157A3 (hu)
HU (1) HUP0102839A3 (hu)
IL (2) IL140837A0 (hu)
MX (1) MXPA01000969A (hu)
NO (1) NO324123B1 (hu)
NZ (1) NZ509348A (hu)
PL (1) PL346361A1 (hu)
WO (1) WO2000006185A2 (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1040837A3 (en) * 1999-02-26 2002-01-02 Erasmus Universiteit Rotterdam Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder
WO2002009739A1 (en) * 2000-07-27 2002-02-07 Novartis Ag Treatment of ocular disorders with somatostatin analogues
US6316414B1 (en) 2000-07-31 2001-11-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
ES2284859T3 (es) 2001-03-06 2007-11-16 Il Consorzio Ferrara Richerche Procedimiento para modular la proliferacion de celulas de carcinoma medular tiroideo.
GB0109461D0 (en) * 2001-04-18 2001-06-06 Univ London New Gene
EP1485117A4 (en) 2002-01-22 2006-03-22 Univ New York METHOD FOR THERAPEUTIC TREATMENT OF BENIGN PROSTATE HYPERTROPHY (BPH)
KR101642363B1 (ko) 2008-06-12 2016-07-25 입센 바이오이노베이션 리미티드 신경내분비계 질환의 억제
CN102083451A (zh) 2008-06-12 2011-06-01 赛恩泰新公司 癌症的抑制
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CN101935252B (zh) * 2010-07-29 2013-01-30 广东省农业科学院科技情报研究所 一种园林植物生长延缓剂及其制备方法
US9333234B2 (en) * 2012-04-12 2016-05-10 Novartis Ag Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
CN105168115A (zh) * 2015-09-02 2015-12-23 中国药科大学 生长抑素类似物多肽药物的口服给药途径
WO2017212390A1 (en) * 2016-06-06 2017-12-14 Emcure Pharmaceuticals Ltd, Process for lanreotide acetate preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
DK0457888T3 (da) * 1989-12-08 1996-08-12 Univ Tulane Octapeptidanaloger af somatostatin med threonin i 6-stillingen
AU3215597A (en) * 1996-08-30 1998-03-19 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
AU4133997A (en) * 1996-09-12 1998-04-02 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
PT980253E (pt) * 1997-05-13 2004-08-31 Conseils De Rec Appl Scient S Somatostatina e agonistas de somatostatina para tratar a insensibilidade a insulina e a sindrome x

Also Published As

Publication number Publication date
CA2335654A1 (en) 2000-02-10
MXPA01000969A (es) 2003-04-07
WO2000006185A3 (en) 2000-08-03
JP2002521456A (ja) 2002-07-16
CN1334742A (zh) 2002-02-06
AR023633A1 (es) 2002-09-04
AU770193B2 (en) 2004-02-12
IL140837A0 (en) 2002-02-10
WO2000006185A2 (en) 2000-02-10
KR20010071071A (ko) 2001-07-28
AU5244799A (en) 2000-02-21
NO324123B1 (no) 2007-08-27
AU2004201783A1 (en) 2004-05-27
CZ2001157A3 (cs) 2002-02-13
NZ509348A (en) 2004-02-27
BR9912609A (pt) 2001-05-02
NO20010481L (no) 2001-03-21
IL181349A0 (en) 2007-07-04
HUP0102839A3 (en) 2002-02-28
PL346361A1 (en) 2002-02-11
EP1100532A2 (en) 2001-05-23
NO20010481D0 (no) 2001-01-29

Similar Documents

Publication Publication Date Title
HUP0102839A2 (hu) Lanreotide-szomatosztatin analóg alkalmazása gyógyszerkészítmények előállítására és az azt tartalmazó gyógyszerkészítmények
AU637882B2 (en) The use of guanidine derivatives for the preparation of a pharmaceutical product having pny antagonistic activity
JP4157601B2 (ja) 置換オキサゾリジンカルパインおよび／またはカテプシンｂ阻害剤
KR100809205B1 (ko) 비아릴옥시메틸아렌-카복실산
US11767311B2 (en) Acid secretion inhibitor and use thereof
NZ199990A (en) 1,4-dihydropyridine derivatives and pharmaceutical compositions
KR860001921B1 (ko) 1,4-디하이드로피리딘의 제조방법
KR950010326B1 (ko) 신규의 이미다졸릴구아니딘 유도체와 그 제법
DE2949491A1 (de) 1,4-dihydropyridine, ihre herstellung und verwendung
EP0508220B1 (de) Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel
KR840001075B1 (ko) 티아졸 유도체의 제조방법
CA1296716C (en) N-(2-substituted alkyl)-n'-[(imidazole-4-yl) alkyl] guanidine
US20040038990A1 (en) Aminothiazole derivatives
CN1307166C (zh) HPPAR－α受体的噁唑/噻唑衍生物活化剂
JP2755385B2 (ja) ニトロエテン誘導体の製造法
JPS5835185A (ja) ３−メチルフラボン−８−カルボン酸エステル類
US4994476A (en) Dihydropyridin-3,5-dicarboxylates incorporating aryloxypropanolamine moieties
ZA200305100B (en) 2-Arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof.
IL292684A (en) A polypeptide with mmp2 inhibitory effect
WO2005048916A3 (en) Tetrahydrospiro-beta-carboline-1,3 '-pyrrolidine derivatives and their use in ghsr-related disorders
KR880002209B1 (ko) 치환된 3,4-디아미노-1,2,5-티아디아졸류 및 그의 제조방법
US6906166B2 (en) Polymers and oligomers, their synthesis, and electronic devices incorporating same
DE69300318T2 (de) Flavonderivate.
RU2001105926A (ru) Способы применения аналога соматостатина
JP3119017B2 (ja) 新規な抗菌性化合物、その製造方法および用途

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees